CX3CR1 and Parkinson disease: CX3CR1 deficiency results in microglia activation and increased neurodegeneration after LPS injections in PD and amyotrophic lateral sclerosis (ALS) mouse models [43,67] and worsens Alzheimer’s disease (AD)-related neuronal deficits associated with microglial activation and elevated chemokines [43].